SpyGlass Pharma Q1 2026 Financial Results and Updates
Health
Earnings
IPO:
Feb 06, 2026
Industry:
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Corporate Updates
May 14, 2026 5:28 PM ET
Aliso Viejo, Calif. - SpyGlass Pharma (Nasdaq: SGP), a late-stage biopharmaceutical company, announced its financial results for the first quarter ending March 31, 2026, alongside key updates on its clinical programs.
Key Highlights:
... Read on — Members only
About SpyGlass Pharma, Inc.
We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
More SGP News
Health
Daily overview of upcoming SPAC and IPO events – from initial announcement to definitive agreement and public listing.
Discover last week’s SPAC and IPO highlights, key trends, and market updates. Stay informed with SpacStar.